ClinicalTrials.gg
CompletedNCT05406817Updated Jan 10, 2025

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

A Phase 1 interventional study of Revumenib in Acute Leukemia, sponsored by Syndax Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Syndax Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,668 studies in Leukemia with a site in United States — 115 open to participants now, 183 under way, 11 of them phase 3. Leukemia · United States.

Enrollment
1,113th of 1,350
9 · median 35
Started
2022
with 21 others
Phase 1
410 of 1,668
28 open now
Registered
1,558th of 1,668
by date

Among the 1,668 studies in Leukemia with a site in United States, this one is the 1,113th largest by enrollment of the 1,350 interventional ones that give a count, is one of 22 that started in 2022, is one of 410 in phase 1, and was the 1,558th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

115 of the 1,668 studies in Leukemia with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,668 studies in Leukemia with a site in United States, or all of them as a file.
02

Study summary

This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 ([14C])-revumenib in participants with acute leukemia.

Read the detailed description

Participants will be enrolled in this study primarily to complete the 11-day AME portion of the study; participants who are receiving benefit from revumenib may remain on study until progressive disease (PD) or unacceptable toxicity.

03

Conditions studied

  • Acute Leukemia

Browse trials for

Keywords

  • SNDX-5613
  • Acute Leukemia
  • Refractory leukemia
  • Relapsed leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females (of non-) aged ≥18 years
  • acute leukemia, including participants who are MRD-positive by multiparametric flow cytometry or next-generation sequencing, and including participants with isolated extramedullary disease.
  • Previously received standard of care therapy
  • (ECOG) performance status score of 0 to 2
  • Adequate liver and cardiac function
  • Fertile males agree to use barrier from the time of enrollment through 120 days after the last study drug dose

Key Exclusion Criteria:

  • Active diagnosis of acute promyelocytic leukemia
  • White blood cell (WBC) count >25,000/microliters at time of enrollment.
  • Detectable viral load within the previous 6 months
  • or
  • Cardiac, gastrointestinal, or (GVHD)
  • History of or any concurrent condition, therapy, laboratory abnormality, or allergy to that might confound the results of the study, interfere with the participant's ability to participate for the full duration of the study, or not be in the best interest of the participant to participate
  • Must not be receiving any moderate or strong cytochrome P450 3A4 () inhibitor/inducers
  • Any commercially available or antileukemic therapy other than revumenib except for short-term administration of and/or hydroxyurea for cytoreduction
  • Participation in another therapeutic interventional clinical study in which an investigational agent was administered within 30 days before starting revumenib
  • Any concurrent systemic treatment to prevent GVHD
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Revumenib

    Participants will be administered a single dose of revumenib (containing \~100 microcuries \[14C\]-revumenib) in the AME part of the study. Each dose administered after the first dose in the AME part of the study will be nonradiolabeled revumenib. revumenib may continue to be administered following completion of the AME part of the study. Doses will be administered in continuous 28-day cycles until either PD or unacceptable toxicity.

    Drug: Revumenib

Interventions

  • Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.

    Also known as: SNDX-5613

06

What researchers measure

Primary outcomes

  1. Percentage of Dose Excreted in Urine (feu)

    Time frame: Up to Day 11

  2. Percentage of Dose Excreted in Feces (fef)

    Time frame: Up to Day 11

  3. Amount Excreted in Urine (Aeu)

    Time frame: Up to Day 11

  4. Amount Excreted in Feces (Aef)

    Time frame: Up to Day 11

  5. Area Under The Concentration Time Curve from Time 0 to The Last Measurable Concentration (AUC0-t)

    Time frame: Up to Day 21

  6. Maximum Observed Concentration (Cmax)

    Time frame: Up to Day 21

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: up to approximately 1 year

07

Study locations

1 site
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2024, 27 months.

Of 51 industry-sponsored phase 1 interventional studies under Leukemia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 27 months is below that.

Counting every sponsor, half of 164 studies reached it within 53 months; a quarter within 34 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 7, 2022
StartActual
Aug 5, 2022
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05406817
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Aug 5, 2022
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Jan 10, 2025

Study contacts

Nicole McNeer, MD, PhD
study director · Syndax Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Revumenib

Start the discussion